Ernest BeutlerStephan DuparcOgobara DoumboKanjaksha GhoshMarcus Vinicius Guimaraes De LacerdaDidier LapierreSornchai LooareesuwanZulfiqarali PremjiTom VulliamyChristopher WhittyScripps Research InstituteInternational Center CointrinUniversity of Bamako Faculty of Medicine, Pharmacy and Odonto-StomatologyInstitute of Immunohaematology MumbaiFundacao de Medicina Tropical do AmazonasGlaxoSmithKline plc.Mahidol UniversityUniversity of Dar Es SalaamImperial College LondonLondon School of Hygiene & Tropical Medicine2018-08-242018-08-242007-10-01American Journal of Tropical Medicine and Hygiene. Vol.77, No.4 (2007), 779-789000296372-s2.0-38449090020https://repository.li.mahidol.ac.th/handle/20.500.14594/24511Glucose-6-phosphate dehydrogenase (G6PD) deficiency is relatively common in populations exposed to malaria. This deficiency appears to provide some protection from this infection, but it can also cause hemolysis after administration of some antimalarial drugs, especially primaquine. The risk of drug-induced G6PD deficiency-related hemolysis depends on a number of factors including the G6PD variant, the drug and drug dosage schedule, patient status, and disease factors. Although a great deal is known about the molecular biology of G6PD, determining the potential for drug-induced hemolysis in the clinical setting is still challenging. This report discusses the potential strategies for assessing drug-induced G6PD deficiency-related hemolytic risk preclinically and in early clinical trials. Additionally, the issues important for conducting larger clinical trials in populations in which G6PD deficiency is prevalent are examined, with a particular focus on antimalarial drug development. Copyright © 2007 by The American Society of Tropical Medicine and Hygiene.Mahidol UniversityImmunology and MicrobiologyMedicineReviewSCOPUS